136 related articles for article (PubMed ID: 24959297)
1. Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma.
Numakura K; Tsuchiya N; Akihama S; Inoue T; Narita S; Huang M; Satoh S; Habuchi T
Oncol Lett; 2014 Jul; 8(1):464-466. PubMed ID: 24959297
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
Staehler M; Haseke N; Roosen A; Stadler T; Bader M; Siebels M; Karl A; Stief CG
Eur J Med Res; 2010; 15(7):287-91. PubMed ID: 20696639
[TBL] [Abstract][Full Text] [Related]
3. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
Nanus DM; Garino A; Milowsky MI; Larkin M; Dutcher JP
Cancer; 2004 Oct; 101(7):1545-51. PubMed ID: 15378501
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
Michaelson MD; McKay RR; Werner L; Atkins MB; Van Allen EM; Olivier KM; Song J; Signoretti S; McDermott DF; Choueiri TK
Cancer; 2015 Oct; 121(19):3435-43. PubMed ID: 26058385
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.
Plimack ER; Tan T; Wong YN; von Mehren MM; Malizzia L; Roethke SK; Litwin S; Li T; Hudes GR; Haas NB
Oncologist; 2014 Apr; 19(4):354-5. PubMed ID: 24674872
[TBL] [Abstract][Full Text] [Related]
6. Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases.
Areses MC; Herranz UA; Ferrán BB; Mateos LL; González JG; López RL
Med Oncol; 2012 Jun; 29(2):795-8. PubMed ID: 21560067
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503.
Jay R; McKay RR; Werner L; Atkins MB; Van Allen EM; Olivier KM; Song J; Signoretti S; McDermott DF; Choueiri TK
Urol Oncol; 2017 Mar; 35(3):117-118. PubMed ID: 28159495
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.
Haas NB; Lin X; Manola J; Pins M; Liu G; McDermott D; Nanus D; Heath E; Wilding G; Dutcher J
Med Oncol; 2012 Jun; 29(2):761-7. PubMed ID: 21298497
[TBL] [Abstract][Full Text] [Related]
9. Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma.
Roubaud G; Gross-Goupil M; Wallerand H; de Clermont H; Dilhuydy MS; Ravaud A
Oncology; 2011; 80(3-4):214-8. PubMed ID: 21720184
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.
Park I; Lee HJ; Bae WK; Yoon S; Lee JL
Invest New Drugs; 2019 Dec; 37(6):1239-1246. PubMed ID: 31231787
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report.
Yaegashi H; Izumi K; Konaka H; Mizokami A; Namiki M
J Med Case Rep; 2015 Nov; 9():261. PubMed ID: 26582158
[TBL] [Abstract][Full Text] [Related]
13. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy.
Anraku T; Hashidate H; Nakahara A; Imai T; Kawakami Y
BMC Urol; 2023 Mar; 23(1):38. PubMed ID: 36934227
[TBL] [Abstract][Full Text] [Related]
15. Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.
Noguchi G; Tsutsumi S; Yasui M; Ohtake S; Umemoto S; Nakaigawa N; Yao M; Kishida T
BMC Urol; 2018 Apr; 18(1):26. PubMed ID: 29669553
[TBL] [Abstract][Full Text] [Related]
16. Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications.
Miolo G; Ash A; Buonadonna A; Lo Re G; Torrisi E; Cervo S; Santeufemia DA; Tuzi A; Canzonieri V
Cancer Biol Ther; 2014; 15(11):1439-43. PubMed ID: 25482943
[TBL] [Abstract][Full Text] [Related]
17. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
18. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
[TBL] [Abstract][Full Text] [Related]
19. Sarcomatoid renal cell carcinoma: a case report and literature review.
Liang X; Liu Y; Ran P; Tang M; Xu C; Zhu Y
BMC Nephrol; 2018 Apr; 19(1):84. PubMed ID: 29636020
[TBL] [Abstract][Full Text] [Related]
20. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
